Navigation Links
High-Dose Statins May Increase Diabetes Risk
Date:6/21/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, June 21 (HealthDay News) -- High doses of the widely popular cholesterol-lowering drugs known as statins may have a downside.

A new meta-analysis finds that intensive doses of statins, such as Lipitor and Zocor, upped the risk of being diagnosed with type 2 diabetes compared with moderate doses of the drugs.

But the review still revealed a lower incidence of heart attacks, stroke and death, meaning the balance remains tipped in favor of taking statins to protect your heart.

"The benefit with respect to heart protection still favors high-dose statins because those taking high doses of statins often have heart disease so are at very high risk of further events," said Dr. Kausik K. Ray, senior author of a paper published in the June 22/29 issue of the Journal of the American Medical Association.

"Patients should get annual checks of blood sugars and, if elevated, be treated appropriately," added Ray, a professor of cardiovascular disease prevention at St. George's University of London. "Of the agents tested, the net benefit was better with high-dose atorvastatin [Lipitor] as compared with high-dose simvastatin [Zocor]."

Statins have been very successful in lowering cholesterol levels and are used in people with and without diabetes, which is a major risk factor for cardiovascular disease.

According to Ray, only about 20 percent of patients taking statins are on high doses. About 80 percent take low to moderate doses.

Ray, along with colleagues from the University of Glasgow, pooled data from five randomized studies comparing intensive statin treatment with more moderate doses.

Essentially, all of the studies involved Lipitor and Zocor, either comparing them against each other, or comparing different doses of the same medication.

All together, they involved almost 33,000 participants and an average follow-up of almost five years.

People taking high doses (80 milligrams) of one of these drugs had a 12 percent higher risk for new-onset diabetes but a 16 percent reduced risk of cardiovascular events, compared with moderate doses.

That translates to one new case of diabetes for every 500 patients treated for one year with a high-dose statin compared with one fewer patient having a stroke or heart attack for every 155 patients treated for one year.

But the study had a number of limitations, other experts stated.

For one thing, it was a meta-analysis which, says Dr. Jacob Warman, chief of endocrinology at the Brooklyn Hospital Center in New York City, "doesn't prove anything." These types of analyses tend to be more "hypothesis-generating." (When researchers conduct a meta-analysis, they synthesize previous studies to look for patterns that would not show up in an individual study).

"It's suggestive but I don't know that it's conclusive," added Dr. Steven D. Wittlin, clinical director of the diabetes service at the University of Rochester Medical Center in Rochester, N.Y.

While there was a benefit seen in macrovascular complications, such as heart attacks, it's unclear if the same would be true with microvascular complications or those that involve small blood vessels and contribute to conditions such as neuropathy, Wittlin said.

That could change the risk-benefit ratio, he noted.

Also, as the authors themselves pointed out, the biological mechanisms behind the effect are still not clearly understood.

More information

The U.S. Food and Drug Administration has more on statins.

SOURCES: Jacob Warman, M.D., chief of endocrinology, Brooklyn Hospital Center, New York City; Steven D. Wittlin, M.D., clinical director, endocrine-metabolism division, and director, Diabetes Service, University of Rochester Medical Center, Rochester, N.Y.; Kausik K. Ray, M.D., professor of cardiovascular disease prevention, St. George's University of London; June 22/29, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High-Dose Vitamin B Risky for Diabetics With Kidney Disease
2. New model may simplify high-dose radiosurgery planning
3. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
4. Statins May Benefit Prostate Cancer Patients
5. Alternative to Statins Shows Promise
6. Statins may slow progression of multiple sclerosis, new study finds
7. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
8. Do Statins Lower Male Sex Drive?
9. Statins Wont Lower Colon Cancer Risk
10. Statins decrease risk of clot-related diseases
11. Some statins have unintended effects and warrant closer monitoring, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-Dose Statins May Increase Diabetes Risk
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology: